Pharmaceutical Sourcing and Onshoring Survey – 2022 Edition

Pages: 36 Published: July 29, 2022 Report Code: GDUKPHAR100058

Recent geopolitical events are causing the pharma industry to consider its supply chain more carefully than ever. Highly developed pharma markets rely on foreign suppliers for their drugs, especially China and India. The COVID-19 pandemic, rising raw material and fuel costs, Russia’s war against Ukraine, and other events are prompting industry conversations about drug shortages and supply chain security.

In this report, GlobalData assesses the outlook for pharmaceutical supply chains over the next 12 months, to determine to what extent bio/pharmaceutical companies and their service providers are concerned, and whether they plan to “onshore” or “offshore” their manufacturing steps.

Scope

Who should buy this report?

This 36-page report gives important, expert insight you won’t find in any other source. 17 figures throughout the report illustrate major points and trends. This report is required reading for:

• CMO executives who must have deep understanding of the pharmaceutical supply chain to make strategic planning and investment decisions.

• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

Overview of supply chain trends and key stakeholders' attitudes to onshoring and sourcing

Detailed survey of industry plans to change sourcing strategy

Analysis by geography, drug molecule type, company type, manufacturing step (active pharmaceutical ingredient, finished dose form, packaging)

Table of Contents

About GlobalData

Study Design

Respondent Mix

The Onshoring Question

Other Supply Chain Challenges

Key Findings

Appendix

Contact Us

List of Figures

Survey Respondent Mix: Company Geography

Respondent Mix by Seniority Level

Respondent Mix by Company Size

Respondent Mix by Company’s Business Type

Respondent Mix by Drug Portfolio

The Pharma Supply Chain

Supply Chain Evolution for API Over the Next 12 Months

Reasons for Onshoring API Over the Next 12 Months

Supply Chain Evolution for Finished Dose and Packaging Over the Next 12 Months

Reasons for Onshoring Dose/Packaging Over the Next 12 Months

FDA-Registered Facilities

Onshoring Plans – by Drug Type (1)

Onshoring Plans – by Drug Type (2)

Onshoring – Will It Work? (1)

Onshoring – Will It Work? (2)

Challenges for the Next 12 Months – by Company Geography

Challenges for the Next 12 Months – by Company Business Model

Key Findings

Frequently Asked Questions

Enquire Before Buying
$4995

Can be used by individual purchaser only

$14985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.